Quince Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Quince Therapeutics, Inc. carries a market capitalization of 8.83M, placing it among publicly traded companies globally. Its enterprise value stands at -97.48M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 8.83M |
| Enterprise Value | -97.48M |
Share Statistics
Quince Therapeutics, Inc. currently has 1.02M shares outstanding.
| Shares Outstanding | 1.02M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.52 |
| P/TBV Ratio | -0.52 |
| P/FCF Ratio | -0.89 |
| P/OCF Ratio | -0.89 |
Financial Position
Quince Therapeutics, Inc. maintains a current ratio of 14.52, meaning it holds 14.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 14.52 |
| Quick Ratio | 14.23 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -730.19 |
| Return on Assets (ROA) | -76.68 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -2.16M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Quince Therapeutics, Inc.'s stock has declined approximately -91.42432% over the past 52 weeks. The 50-day moving average sits at 30.84, while the 200-day moving average is 82.02.
| Beta (5Y) | N/A |
| 52-Week Price Change | -91.42432% |
| 50-Day Moving Average | 30.84 |
| 200-Day Moving Average | 82.02 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -60.65M, while operating income came in at -60.80M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -60.80M |
| Pretax Income | -94.64M |
| Net Income | -92.48M |
| EBITDA | -60.65M |
| EBIT | -60.80M |
| Earnings Per Share (EPS) | -40.43 |
Balance Sheet
Total book value stands at -35.32M, with working capital of 114.91M providing operational flexibility.
| Cash & Cash Equivalents | 115.98M |
| Total Debt | N/A |
| Net Debt | -115.98M |
| Equity (Book Value) | -35.32M |
| Book Value Per Share | -34.73 |
| Working Capital | 114.91M |
Cash Flow
Quince Therapeutics, Inc. produced -46.92M in operating cash flow over the past twelve months. After subtracting -78,000.00 in capital expenditures, free cash flow totaled -47.00M - equivalent to -20.55 per share.
| Operating Cash Flow | -46.92M |
| Capital Expenditures | -78,000.00 |
| Free Cash Flow | -47.00M |
| FCF Per Share | -20.55 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -658.29 |
| FCF Yield | -112.59 |
Stock Splits
Quince Therapeutics, Inc.'s most recent stock split took place on June 30, 2026 with a 20:1 split ratio.
| Last Split Date | 6/30/2026 |
| Split Ratio | 20:1 |
Scores
Quince Therapeutics, Inc. posts an Altman Z-Score of -6.08, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -6.08 |